EvidenceHunt raises €1.2M for medical data analysis platform

Netherlands-based EvidenceHunt, an AI-powered medical research platform that allows medical professionals to analyse medical data, has closed a funding round of €1.2M led by Keen Venture Partners, Dff.ventures and Slimmer AI. 

The consortium was joined by notable angel investors, including Jeroen Tas (former Chief Strategy and Innovation Officer at Philips), Dinko Valerio (former CEO and Founder of Crucell), and James Shannon (former Head of Global Drug Development Novartis).

EvidenceHunt is an AI-powered research platform designed to streamline the process of gathering, analysing, and utilising medical evidence. It enables users to quickly find and summarize biomedical publications, making complex medical literature more accessible and understandable. The platform offers features such as customizable weekly e-alerts to keep users updated on the latest clinical trials, evidence in specific disease areas, and information on particular drugs. Its user-friendly interface, developed by a multidisciplinary team, ensures efficient navigation and retrieval of relevant clinical evidence, thereby supporting healthcare professionals in making informed decisions.

The platform launched 1.5 years ago; since then, it has grown to a global user base of 25,000 users, including healthcare professionals, medical science experts, researchers and students. The company plans to use the funding to extend the platform’s capabilities, enabling teams and organizations to efficiently process medical information.

“As a medical doctor and PhD, I know firsthand how frustrating it can be to spend countless hours navigating PubMed, guidelines, and protocols. From day one, we built EvidenceHunt to mimic domain-specific logic and processes for evaluating and interpreting literature. But we aim to do more than just save time - we provide clear answers that users can trace back to credible sources. Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability, which are essential for adoption and for earning the trust of the medical community.” said Philippe Habets, CEO.

Investor JC Heyneke from Slimmer AI, and former GM at Elsevier, commented: “EvidenceHunt addresses a clear pain point for users across various segments worldwide. By integrating into institutional workflows and with institutional data, and applying the latest LLM technology in a powerful vertical-AI SaaS solution, EvidenceHunt taps into a large and growing market.”